Risks and benefits of taxanes in breast and ovarian cancer

Drug Safety

Volumn 23, Issue 5, 2000, Pages 401-428

  Michaud, Laura Boehnke ^a   Valero, Vicente ^a   Hortobagyi, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE;

ARTHRALGIA; BREAST CANCER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HUMAN; MYALGIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 0033767619     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023050-00005     Document Type: Review

References (147)

1. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
2. Promotion of microtubule assembly in vitro by taxol
3. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind
4. Application of the vicinal oxymination reaction with asymmetric induction to the hemisynthesis of taxol and analogues
5. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of pacific yew
6. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences
7. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs
8. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
9. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel
10. Drug delivery systems: Water soluble taxol 2'-poly(ethylene glycol) ester prodrags- design and in vivo effectiveness
11. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
12. An investigation of the antitumor activity and biodistribution of polymeric micellar paclitaxel
13. Tubulin polymerization by paclitaxel (Taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase
14. Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours
15. Limited oral bio-availability and active epithelial excretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine
16. Enhanced oral bioavailability of paclitaxel in mice treated with the p-glycoprotein blocker SDZ PSC 833
17. Phase I and pharmacokinetic study of oral paclitaxel
18. Cyclosporin a strongly enhances the oral bioavailability of docetaxel in cancer patients
19. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion
20. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion
21. Phase I trial of taxotere: Five-day schedule
22. Phase I Study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
23. Polysorbate 80 hypersensitivity
24. Cytostatic and apoptotic effects of paclitaxel in human breast tumors
25. Mechanisms of Taxol-induced cell death are concentration dependent
26. 3'-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino acids of β-tubulin
27. Feulgen-DNA, 'bundles' by measurement of fluorescence, Demonstration of the cell cycle positions for taxol-induced 'asters', content, and autoradiographic labeling of the same cells
28. Development of polyploidization in taxol-resistant human leukemic cells in vitro
29. Mechanism of action of taxol
30. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
31. Effects of Taxotere on murine and human tumor cell lines
32. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line
33. The taxoids: Paclitaxel (Taxol®) and docetaxel (Taxotere®)
34. Solution structure of taxotere-induced microtubules to 3-nm resolution: The change in protofilament numberis linked to the binding of the taxol side chain
35. Differential effects of Taxol or Taxotere on Tau and MAP2 containing microtubules [abstract]
36. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
37. Microtubule-damaging drags triggered bcl2 phosphorylation - Requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein
38. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
39. Taxol resistant mutants of chinese hamster ovary cells: Genetic, biochemical, and cross-resistance studies
40. Establishment and characterization of docetaxel (Taxotere) resistant human breast carcinoma (Calc 18/TXT) and murine leukemic (P388/TXT) cell lines
41. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly
42. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
43. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
44. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
45. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
46. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
47. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol
48. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
49. A phase I trial of taxol given by 6-hour intravenous infusion
50. Paclitaxel in doxorubicinrefractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
51. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
52. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors
53. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans
54. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion
55. Evaluation of the linearity of docetaxel pharmacokinetics
56. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
57. Metabolism of docetaxel by human cytochrome P450: Interactions with paclitaxel and other antineoplastic drugs
58. Sequences of taxol and cisplatin: A phase I and pharmacologic study
59. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
60. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
61. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer
62. Review of docetaxel/doxorubicin combination in metastatic breast cancer
63. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
64. Phase I clinical and pharmacokinetic study of Taxol
65. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial
66. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
67. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26
68. Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (PT) with metastatic breast cancer (MBC)
69. Compounding an extended-stability admixture of paclitaxel for long-term infusion
70. Phase I study of paclitaxel
71. Failure of higher dose paclitaxel to improve outcome in patient with metastatic breast cancer - Results from CALGB 9342
72. 2 in pretreated patients (pts) with breast (BC) and ovarian cancer (OC)
73. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
74. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: A preliminary report
75. Docetaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer
76. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy
77. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
78. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
79. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264
80. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
81. A phase Ii trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer
82. Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere® (T)
83. The M.D. Anderson Cancer Center experience with taxol in metasiatic breast cancer
84. Phase II trial of paclitaxel by 3-hour infusion as initial and Salvage chemotherapy for metastatic breast cancer
85. Phase III trial of paclitaxel (P) administered over 3- or 96-HR for metastatic breast cancer (MBC)
86. Paclitaxel (Taxol): Phase I/II trial comparing 1-hour infusion schedules
87. American Society of Clinical Oncotogy Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidenced-based clinical practice guidelines
88. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
89. Safety evaluation of two doses of Taxotere (docetaxel) without routine premedication as first line in advanced breast cancer (ABC) - EORTC Clinical Screening Group (CSG) report
90. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis
91. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
92. Infusion site soft-tissue injury after paclitaxel administration
93. Docetaxel
94. Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention
95. Hypersensitivity reactions from Taxol
96. Successful re-treatment with Taxol after major hypersensitivity reactions
97. Paclitaxel rechallenge failure after a major hypersensitivity reaction J Clin Oncol
98. Cardiac disturbances during the administration of taxol
99. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
100. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer
101. Sequence-dependent hematologic toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet
102. Typhlitis associated with docetaxel treatment
103. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
104. Paclitaxel efficacy in patients with advanced breast cancer resistant to anthracyclines
105. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
106. The taxoids: Comparative clinical pharmacology and therapeutic potential
107. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
108. Phase III trial of doxombicin (A) vs. paclitaxel (T) vs. doxombicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
109. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer
110. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
111. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
112. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
113. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
114. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
115. Update: The M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma
116. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer
117. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
118. Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and Doxorubicin/Taxol® (paclitaxel) (AT) as neo-adjuvant treatment of local-regional breast cancer
119. Pathological response to neoadjuvant chemotherapy (CT): Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification
120. Phase III multicenter trial companng taxol®/doxorubicin (AT) vs 5-fluorouracil/ doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer
121. Doxombicin and docetaxel (AT) is superior to standard doxombicin and cyclophosphamide (AC) as 1st line CT for MBC: Randomized phase III trial
122. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
123. Docetaxel in combination with doxombicin: A phase I dose-finding study
124. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
125. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
126. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment for advanced ovarian cancer (OVCA)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup experience
127. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergoup Trial
128. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer
129. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
130. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
131. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
132. A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer
133. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
134. Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: Preliminary results of a phase I study
135. Randomized phase III study in previously untreated epithelial ovar an cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin
136. Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer
137. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study 132
138. Cisplatin-docetaxel (Taxotere) in first line treatment of advanced ovarian cancer (OC): A GINECO phase II trial
139. A phase II study in advanced Ovarian cancer with Taxotere, cisplatinum and cyclophosphamide
140. Paclitaxel vs CAP (cyclophosphamide, Adriamycin, cisplatin) in recurrent platinum-sensitive ovarian cancer: A randomized phase II study
141. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
142. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine
143. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer
144. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients